109 related articles for article (PubMed ID: 8865125)
21. [The value of measuring the serum level of soluble interleukin-2 receptors in lung cancer patients].
Siemińska A
Pol Merkur Lekarski; 2004 Feb; 16(92):188-90. PubMed ID: 15176308
[TBL] [Abstract][Full Text] [Related]
22. Serum-soluble interleukin-2 receptor concentrations in patients with gastric cancer.
Murakami S; Satomi A; Ishida K; Murai H; Matsuki M; Hashimoto T
Cancer; 1994 Nov; 74(10):2745-8. PubMed ID: 7525035
[TBL] [Abstract][Full Text] [Related]
23. Serum soluble interleukin-2 receptor (IL-2R) and immunohistochemical staining of IL-2R/Tac antigen in colorectal cancer.
Sakata H; Murakami S; Hirayama R
Int J Clin Oncol; 2002 Oct; 7(5):312-7. PubMed ID: 12402066
[TBL] [Abstract][Full Text] [Related]
24. Soluble interleukin-2 receptor in sera of patients with pulmonary tuberculosis.
Takahashi S; Setoguchi Y; Nukiwa T; Kira S
Chest; 1991 Feb; 99(2):310-4. PubMed ID: 1989787
[TBL] [Abstract][Full Text] [Related]
25. Interleukin-2 receptors in pulmonary adenocarcinoma tissue.
Yano T; Fukuyama Y; Yokoyama H; Takai E; Tanaka Y; Asoh H; Ichinose Y
Lung Cancer; 1996 Dec; 16(1):13-9. PubMed ID: 9017581
[TBL] [Abstract][Full Text] [Related]
26. Serum levels of sFas and sFasL during chemotherapy of lung cancer.
Naumnik W; Izycki T; Ossolinska M; Chyczewska E
Exp Oncol; 2007 Jun; 29(2):132-6. PubMed ID: 17704746
[TBL] [Abstract][Full Text] [Related]
27. Soluble interleukin-2 receptors in pulmonary tuberculosis.
Ito M; Kojiro N; Shirasaka T; Ikeda T; Tachibana I; Mima T; Kokubu T
Jpn J Med; 1990; 29(6):583-6. PubMed ID: 2101408
[TBL] [Abstract][Full Text] [Related]
28. Serum soluble interleukin 2 (IL-2) receptor (sIL-2R) in differentiated thyroid carcinoma.
Mariotti S; Barbesino G; Caturegli P; Marinò M; Manetti L; Fugazzola L; Pacini F; Pinchera A
J Endocrinol Invest; 1994 Dec; 17(11):861-7. PubMed ID: 7745234
[TBL] [Abstract][Full Text] [Related]
29. Soluble interleukin-2 receptor alpha is elevated in sera of patients with benign ovarian neoplasms and epithelial ovarian cancer.
Hurteau JA; Woolas RP; Jacobs IJ; Oram DC; Kurman CC; Rubin LA; Nelson DL; Berchuck A; Bast RC; Mills GB
Cancer; 1995 Nov; 76(9):1615-20. PubMed ID: 8635066
[TBL] [Abstract][Full Text] [Related]
30. [Prognostic factors in patients with stage III and IV non-small cell lung cancer].
Song LH; Song XR; Liu MQ; Zhang XQ; Zheng L; Li XJ; Liu PX
Zhonghua Zhong Liu Za Zhi; 2004 Jun; 26(6):345-8. PubMed ID: 15312344
[TBL] [Abstract][Full Text] [Related]
31. [Clinical usefulness of a new tumor marker CYFRA21-1 in patients with lung cancer].
Li R; Li R; Wang Y
Zhonghua Jie He He Hu Xi Za Zhi; 1998 Jan; 21(1):26-9. PubMed ID: 11263296
[TBL] [Abstract][Full Text] [Related]
32. Levels of serum-soluble receptor for interleukin-2 in patients with colorectal cancer.
Saito H; Tsujitani S; Katano K; Ikeguchi M; Maeta M; Kaibara N
Surg Today; 1998; 28(10):1115-7. PubMed ID: 9786595
[TBL] [Abstract][Full Text] [Related]
33. Soluble interleukin 2 receptor in lung cancer. An indirect marker of tumor activity?
Buccheri G; Marino P; Preatoni A; Ferrigno D; Moroni GA
Chest; 1991 Jun; 99(6):1433-7. PubMed ID: 2036827
[TBL] [Abstract][Full Text] [Related]
34. Pretreatment serum levels of cytokines and cytokine receptors in patients with non-small cell lung cancer, and correlations with clinicopathological features and prognosis. M-CSF - an independent prognostic factor.
Kaminska J; Kowalska M; Kotowicz B; Fuksiewicz M; Glogowski M; Wojcik E; Chechlinska M; Steffen J
Oncology; 2006; 70(2):115-25. PubMed ID: 16645324
[TBL] [Abstract][Full Text] [Related]
35. [Level and significance of the soluble interleukin-2 receptor expression in serum of patients with bladder cancer].
Wen R; Xie S; Ma P
Zhonghua Wai Ke Za Zhi; 1996 Jan; 34(1):16-8. PubMed ID: 9275680
[TBL] [Abstract][Full Text] [Related]
36. [A study on interleukin 2 and soluble interleukin 2 receptor in serum and bronchoalveolar lavage fluid from patients with farmer's lung].
Ninomiya Y; Obara A; Sugawara K; Konishi K
Nihon Kyobu Shikkan Gakkai Zasshi; 1991 Nov; 29(11):1399-406. PubMed ID: 1770680
[TBL] [Abstract][Full Text] [Related]
37. Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer--TIMP-1 as a prognostic marker.
Ylisirniö S; Höyhtyä M; Turpeenniemi-Hujanen T
Anticancer Res; 2000; 20(2B):1311-6. PubMed ID: 10810441
[TBL] [Abstract][Full Text] [Related]
38. Chronic effects of subcutaneous interleukin-2 therapy on soluble interleukin-2 receptors in advanced small cell lung cancer.
Viviani S; Salvini PM; Bidoli P; Camerini E; Spinazzé S; Arienti F; Rivoltini L; Motta V
Int J Biol Markers; 1993; 8(1):21-4. PubMed ID: 8388428
[TBL] [Abstract][Full Text] [Related]
39. Serum levels of soluble interleukin-2 receptor in renal cell carcinoma.
Matsumoto T; Furukawa A; Sumiyoshi Y; Akiyama KY; Kanayama HO; Kagawa S
Urology; 1998 Jan; 51(1):145-9. PubMed ID: 9457310
[TBL] [Abstract][Full Text] [Related]
40. [The role of serum soluble interleukin 2 receptor (sIL-2R) levels in patients with renal cell carcinoma].
Akiyama K; Tsuji M; Kurokawa Y; Yokota K; Kojima K; Naruo S; Kanayana HO; Kagawa S
Nihon Hinyokika Gakkai Zasshi; 1997 Apr; 88(4):473-8. PubMed ID: 9155114
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
